Purdue Pharma

5 Stories

11-Year-Olds Can Now Be Prescribed OxyContin

FDA approves drug for severe pain in kids 11 to 16

(Newser) - The FDA has approved the powerful painkiller OxyContin for a new use in children 11 to 16 who are suffering from severe, long-term pain. OxyContin is an extended-release opioid that has long been used to treat around-the-clock pain in adults. But most pain medications are not approved for use in... More »

Combo Painkiller Designed to Be Tougher to Abuse

FDA approves opioid that won't cause euphoria when crushed

(Newser) - The FDA has approved a new form of OxyContin that unites two unlikely bedfellows in an attempt to curb abuse, reports AP . The drug from Purdue Pharma is called Targiniq ER, and it combines oxycodone—the main painkilling ingredient in OxyContin, one that causes feelings of euphoria—with naloxene, which... More »

Oxy Maker Won't Share List of Suspicious Doctors

Purdue Pharma has IDed 1,800 suspect doctors, but only told authorities about 154

(Newser) - The maker of OxyContin has a database of doctors it suspects may be prescribing its pills to addicts and dealers—but it isn't sharing that info with cops, reports the LA Times . Purdue Pharma says it has alerted authorities to 154 suspicious prescribers, but that's only about 8%... More »

FDA Blocks Generic OxyContin

Move prevents crushable form returning to market

(Newser) - In a big victory for campaigners against prescription drug abuse—as well as for OxyContin maker Purdue Pharma—the FDA has blocked generic drugmakers from making their own versions of the powerful painkiller. The ruling came on the day that Purdue's patent on the old, crushable, and widely abused... More »

OxyContin Maker Pleads Guilty

Manufacturer, execs admit misleading public about risky painkiller

(Newser) - The company that makes OxyContin pleaded guilty today to misleading the public about the effects of the potent painkiller. Purdue Pharma and three executives will pay $634.5 million in civil and criminal fines. Federal prosecutors accused the firm of "misbranding" the drug, marketing it as a less addictive... More »

5 Stories